{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T06:45:15Z","timestamp":1772606715526,"version":"3.50.1"},"reference-count":40,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2002,4,1]],"date-time":"2002-04-01T00:00:00Z","timestamp":1017619200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2002,4,1]],"date-time":"2002-04-01T00:00:00Z","timestamp":1017619200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2014,11,30]],"date-time":"2014-11-30T00:00:00Z","timestamp":1417305600000},"content-version":"vor","delay-in-days":4626,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2002,4]]},"DOI":"10.1046\/j.1469-0691.2002.00392.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T07:27:08Z","timestamp":1047367628000},"page":"214-221","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":63,"title":["In vitro activity of levofloxacin against contemporary clinical isolates of Legionella pneumophila, Mycoplasma pneumoniae and Chlamydia pneumoniae from North America and Europe"],"prefix":"10.1016","volume":"8","author":[{"given":"I.A.","family":"Critchley","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.E.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.D.","family":"Heinze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Hubbard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.D.","family":"Engler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.T.","family":"Evangelista","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Thornsberry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.A.","family":"Karlowsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.F.","family":"Sahm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1046\/j.1469-0691.2002.00392.x_bib1","first-page":"637","article-title":"Treatment of pneumonia: new strategies for changing pathogens","volume":"13","author":"Ashby","year":"1991","journal-title":"Clin Ther"},{"key":"10.1046\/j.1469-0691.2002.00392.x_bib2","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0002-9343(99)00050-9","article-title":"Is Streptococcus pneumoniae the leading cause of pneumonia of unknown etiology? A microbiologic study of lung aspirates in consecutive patients with community-acquired pneumonia","volume":"106","author":"Ruiz-Gonzalez","year":"1999","journal-title":"Am J Med"},{"issue":"suppl 2","key":"10.1046\/j.1469-0691.2002.00392.x_bib3","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1086\/314058","article-title":"Importance of atypical pathogens of community-acquired pneumonia","volume":"31","author":"Plouffe","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.1046\/j.1469-0691.2002.00392.x_bib4","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1128\/AAC.40.5.1175","article-title":"Ofloxacin versus standard therapy in the treatment of community-acquired pneumonia requiring hospitalization","volume":"40","author":"Plouffe","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1046\/j.1469-0691.2002.00392.x_bib5","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1128\/AAC.45.4.1037-1042.2001","article-title":"Need for annual surveillance of antimicrobial resistance in Streptococcus pneumoniae in the United States: 2-year longitudinal analysis","volume":"45","author":"Sahm","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1046\/j.1469-0691.2002.00392.x_bib6","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0732-8893(00)00128-0","article-title":"Benchmarking the in vitro activity of moxifloxacin against recent isolates of Streptococcus pneumoniae, Moraxella catarrhalis, and Haemophilus influenzae. A European multi-centre study","volume":"37","author":"Jones","year":"2000","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1046\/j.1469-0691.2002.00392.x_bib7","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0732-8893(97)00195-8","article-title":"Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States in the 1996-1997 respiratory season","volume":"29","author":"Thornsberry","year":"1997","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1046\/j.1469-0691.2002.00392.x_bib8","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0732-8893(97)00174-0","article-title":"Comparative activity of ciprofloxacin, ofloxacin, levofloxacin and erythromycin against Legionella species by broth microdilution and intracellular susceptibility testing in HL-60 cells","volume":"30","author":"Stout","year":"1998","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1046\/j.1469-0691.2002.00392.x_bib9","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/jac\/37.1.117","article-title":"In vitro activity of levofloxacin against clinical isolates of Legionella spp., its pharmacokinetics in guinea pigs, and use in experimental Legionella pneumophila pneumonia","volume":"37","author":"Edelstein","year":"1996","journal-title":"J Antimicrob Chemother"},{"key":"10.1046\/j.1469-0691.2002.00392.x_bib10","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1093\/jac\/47.2.147","article-title":"Efficacy of moxifloxacin, trovafloxacin, clinafloxacin and levofloxacin against intracellular Legionella pneumophila","volume":"47","author":"Jonas","year":"2001","journal-title":"J Antimicrob Chemother"},{"key":"10.1046\/j.1469-0691.2002.00392.x_bib11","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1128\/AAC.42.12.3153","article-title":"Antibacterial effects of levofloxacin, erythromycin and rifampin in a human monocyte system against Legionella pneumophila","volume":"42","author":"Baltch","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"issue":"suppl S1","key":"10.1046\/j.1469-0691.2002.00392.x_bib12","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1093\/jac\/45.suppl_3.29","article-title":"Comparative potency of gemifloxacin, new quinolones, macrolides, tetracycline and clindamycin against Mycoplasma spp","volume":"45","author":"Duffy","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"10.1046\/j.1469-0691.2002.00392.x_bib13","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1128\/AAC.43.11.2806","article-title":"In vitro activities of gemifloxacin (SB 265805, LB20304) against recent clinical isolates of Chlamydia pneumoniae","volume":"43","author":"Roblin","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1046\/j.1469-0691.2002.00392.x_bib14","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0924-8579(99)00057-6","article-title":"Activity of grepafloxacin and other fluoroquinolones and newer macrolides against recent clinical isolates of Chlamydia pneumoniae","volume":"12","author":"Roblin","year":"1999","journal-title":"Int J Antimicrob Agents"},{"key":"10.1046\/j.1469-0691.2002.00392.x_bib15","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1128\/jcm.30.8.1968-1971.1992","article-title":"Use of HEp-2 cells for improved isolation and passage of Chlamydia pneumoniae","volume":"30","author":"Roblin","year":"1992","journal-title":"J Clin Microbiol"},{"key":"10.1046\/j.1469-0691.2002.00392.x_bib16","series-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, approved standard","year":"2000"},{"key":"10.1046\/j.1469-0691.2002.00392.x_bib17","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1128\/AAC.35.6.1181","article-title":"In vitro susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis and Ureaplasma urealyticum to sparfloxacin and PD127391","volume":"35","author":"Waites","year":"1991","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1046\/j.1469-0691.2002.00392.x_bib18","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1128\/AAC.42.10.2762","article-title":"In vitro susceptibilities of Chlamydia pneumoniae strains recovered from atherosclerotic coronary arteries","volume":"42","author":"Gieffers","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1046\/j.1469-0691.2002.00392.x_bib19","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1128\/AAC.36.3.682","article-title":"In vitro activities of five quinolones against Chlamydia pneumoniae","volume":"36","author":"Hammerschlag","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1046\/j.1469-0691.2002.00392.x_bib20","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1172\/JCI110744","article-title":"Intracellular multiplication of Legionnaires' disease bacteria (Legionella pneumophila) in human monocytes is reversibly inhibited by erythromycin and rifampin","volume":"71","author":"Horwitz","year":"1983","journal-title":"J Clin Invest"},{"key":"10.1046\/j.1469-0691.2002.00392.x_bib21","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/0002-9343(92)90016-5","article-title":"Erythromycin ototoxicity: prospective assessment with serum concentrations and audiograms in a study of patients with pneumonia","volume":"92","author":"Swanson","year":"1992","journal-title":"Am J Med"},{"issue":"suppl S1","key":"10.1046\/j.1469-0691.2002.00392.x_bib22","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/jac\/45.suppl_3.41","article-title":"Comparative in vitro activity and post-antibiotic effect of gemifloxacin against Legionella spp","volume":"45","author":"Dubois","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"10.1046\/j.1469-0691.2002.00392.x_bib23","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1128\/AAC.34.9.1733","article-title":"Comparative postantibacterial activities of perfloxacin, ciprofloxacin and ofloxacin against intracellular multiplication of Legionella pneumophila serogroup 1","volume":"34","author":"Rajagopalan-Levasseur","year":"1990","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1046\/j.1469-0691.2002.00392.x_bib24","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1128\/CMR.2.4.378","article-title":"Fluoroquinolone antimicrobial agents","volume":"2","author":"Wolfson","year":"1989","journal-title":"Clin Microbiol Rev"},{"key":"10.1046\/j.1469-0691.2002.00392.x_bib25","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1128\/AAC.41.9.1965","article-title":"A multicenter, randomized study comparing the efficacy and safety of intravenous and\/or oral levofloxacin versus ceftriaxone and\/or cefuroxime axetil in treatment of adults with community-acquired pneumonia","volume":"41","author":"File","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1046\/j.1469-0691.2002.00392.x_bib26","doi-asserted-by":"crossref","first-page":"328","DOI":"10.7326\/0003-4819-129-4-199808150-00012","article-title":"Antimicrobial chemotherapy for Legionnaires disease: time for change","volume":"129","author":"Edelstein","year":"1998","journal-title":"Ann Intern Med"},{"key":"10.1046\/j.1469-0691.2002.00392.x_bib27","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1093\/jac\/45.3.367","article-title":"In vitro activity of gemifloxacin (SB-265806;LB 20304a) against human mycoplasmas","volume":"45","author":"Hannan","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"10.1046\/j.1469-0691.2002.00392.x_bib28","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S0022-3476(70)80485-1","article-title":"Resistance of Mycoplasma pneumoniae to erythromycin and other antibiotics","volume":"76","author":"Niitu","year":"1970","journal-title":"J Pediatr"},{"issue":"suppl","key":"10.1046\/j.1469-0691.2002.00392.x_bib29","first-page":"83","article-title":"Chemotherapy of Mycoplasma pneumoniae infections in children","volume":"20","author":"Niitu","year":"1990","journal-title":"Zentralbl Bakteriol"},{"key":"10.1046\/j.1469-0691.2002.00392.x_bib30","first-page":"169","article-title":"Antibiotic-resistant mutants of Mycoplasma pneumoniae","volume":"16","author":"Stopler","year":"1980","journal-title":"Israel J Med Sci"},{"key":"10.1046\/j.1469-0691.2002.00392.x_bib31","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1093\/jac\/18.3.359","article-title":"Resistance of Mycoplasma pneumoniae to macrolides, lincomycin and streptogramin B","volume":"18","author":"Stopler","year":"1986","journal-title":"J Antimicrob Chemother"},{"key":"10.1046\/j.1469-0691.2002.00392.x_bib32","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1128\/AAC.5.5.513","article-title":"In vitro development of resistance to erythromycin, other macrolide antibiotics, and lincomycin in Mycoplasma pneumoniae","volume":"5","author":"Niitu","year":"1974","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1046\/j.1469-0691.2002.00392.x_bib33","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1128\/AAC.39.12.2770","article-title":"Transition mutations in the 23S rRNA of erythromycin-resistant isolates of Mycoplasma pneumoniae","volume":"39","author":"Lucier","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1046\/j.1469-0691.2002.00392.x_bib34","first-page":"1574","article-title":"In vitro activities of azithromycin, clarithromycin, L-ofloxacin and other antibiotics against Chlamydia pneumoniae","volume":"36","author":"Hammerschlag","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"issue":"suppl","key":"10.1046\/j.1469-0691.2002.00392.x_bib35","doi-asserted-by":"crossref","first-page":"S460","DOI":"10.1086\/315599","article-title":"Collaborative multidisciplinary workshop: detection, culture, serology and antimicrobial susceptibility testing of Chlamydia pneumoniae","volume":"181","author":"Tompkins","year":"2000","journal-title":"J Infect Dis"},{"issue":"suppl A","key":"10.1046\/j.1469-0691.2002.00392.x_bib36","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/jac\/40.suppl_1.31","article-title":"The in vitro activity of grepafloxacin against Chlamydia spp., Mycoplasma spp., Ureaplasma urealyticum and Legionella spp","volume":"40","author":"Ridgeway","year":"1997","journal-title":"J Antimicrob Chemother"},{"key":"10.1046\/j.1469-0691.2002.00392.x_bib37","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2165\/00003088-199732020-00002","article-title":"The clinical pharmacokinetics of levofloxacin","volume":"32","author":"Fish","year":"1997","journal-title":"Clin Pharmacokinet"},{"key":"10.1046\/j.1469-0691.2002.00392.x_bib38","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1111\/j.1469-0691.1999.tb00705.x","article-title":"Comparative study of levofloxacin and amoxycillin\/clavulanic acid in adults with mild-to-moderate community-acquired pneumonia","volume":"5","author":"Carbon","year":"1999","journal-title":"Clin Microbiol Infect"},{"issue":"suppl S1","key":"10.1046\/j.1469-0691.2002.00392.x_bib39","first-page":"45","article-title":"Levofloxacin vs. ceftriaxone sodium and erythromycin in the treatment of patients with community-acquired pneumonia (CAP) at high risk of mortality","volume":"47","author":"Kahn","year":"2001","journal-title":"J Antimicrob Chemother"},{"issue":"suppl A","key":"10.1046\/j.1469-0691.2002.00392.x_bib40","first-page":"35A","article-title":"Levofloxacin in the treatment of community-acquired pneumonia","volume":"6","author":"File","year":"1999","journal-title":"Can Respir J"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X14636168?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X14636168?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T07:17:43Z","timestamp":1761117463000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X14636168"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,4]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2002,4]]}},"alternative-id":["S1198743X14636168"],"URL":"https:\/\/doi.org\/10.1046\/j.1469-0691.2002.00392.x","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2002,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro activity of levofloxacin against contemporary clinical isolates of Legionella pneumophila, Mycoplasma pneumoniae and Chlamydia pneumoniae from North America and Europe","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1046\/j.1469-0691.2002.00392.x","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2002 European Society of Clinical Infectious Diseases. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}